東陽光(600673.SH):控股子公司非布司他片獲批上市
格隆匯5月14日丨東陽光(600673.SH)宣佈,公司控股子公司東莞市陽之康醫藥有限責任公司於近日收到國家藥品監督管理局(以下簡稱“藥監局”)核准簽發的關於“非布司他片”的《藥品註冊證書》。
非布司他適用於具有痛風症狀的高尿酸血癥的長期治療,不推薦用於無臨牀症狀的高尿酸血癥。非布司他屬於黃嘌呤氧化酶(XO)抑制劑,通過抑制尿酸合成降低血清尿酸濃度,從而達到臨牀治療效果。目前,非布司他片的生產企業主要有江蘇恆瑞醫藥股份有限公司、江蘇萬邦生化醫藥集團有限責任公司、杭州朱養心藥業有限公司等。
非布司他是《國家基本醫療保險、工傷保險和生育保險藥品目錄》2020年版乙類品種。根據艾昆緯數據,2020年中國非布司他藥物銷售金額約為1.98億美元,較2019年增加6.19%。
公司表示,該產品上市後將成為公司在內分泌及代謝的產品之一,在進一步豐富公司的產品組合的同時,也為廣大患者提供質價雙優的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.